Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.36 |
| ▸ | MAPT | P10636 | 3/20 | 0.36 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.36 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.36 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.36 |
| ▸ | CA12 | O43570 | 1/20 | 0.34 |
| ▸ | CA1 | P00915 | 1/20 | 0.34 |
| ▸ | CA2 | P00918 | 1/20 | 0.34 |
| ▸ | GLA | P06280 | 1/20 | 0.34 |
| ▸ | CA3 | P07451 | 1/20 | 0.34 |
| ▸ | CA4 | P22748 | 1/20 | 0.34 |
| ▸ | CA9 | Q16790 | 1/20 | 0.34 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.34 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.34 |
| ▸ | HPGD | P15428 | 1/20 | 0.34 |
| ▸ | TBXAS1 | P24557 | 4/20 | 0.33 |
| ▸ | LMNA | P02545 | 1/20 | 0.33 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.33 |
| ▸ | AKR1C3 | P42330 | 1/20 | 0.33 |
| ▸ | ESR1 | P03372 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Phenol SCHEMBL28648858 | 0.90 | CA12 (0.37) | ALDH1A1MAPTCYP3A4CYP2D6CYP2C19 | |
| Phenol SCHEMBL4622241 | 0.84 | CA12 (0.37) | ALDH1A1MAPTCYP3A4CYP2D6CYP2C19 | |
| SCHEMBL45045 | 0.83 | SQLE (0.32) | ALDH1A1MAPTCYP3A4CYP2D6CYP2C19 | |
| SCHEMBL445817 | 0.83 | SQLE (0.32) | ALDH1A1MAPTCYP3A4CYP2D6CYP2C19 | |
| SCHEMBL9943907 | 0.78 | LMNA (0.47) | ALDH1A1MAPTCYP2D6CYP2C19TDP1 | |
| SCHEMBL443349 | 0.77 | SQLE (0.34) | ALDH1A1MAPTCYP3A4CYP2D6CYP2C19 | |
| SCHEMBL443348 | 0.77 | SQLE (0.34) | ALDH1A1MAPTCYP3A4CYP2D6CYP2C19 | |
| SCHEMBL11507792 | 0.77 | POLB (0.35) | ALDH1A1MAPTCYP3A4CYP2D6CYP2C19 | |
| SCHEMBL11507795 | 0.77 | POLB (0.35) | ALDH1A1MAPTCYP3A4CYP2D6CYP2C19 | |
| Phenol SCHEMBL29171775 | 0.77 | AKR1C3 (0.44) | ALDH1A1MAPTCA12CA1CA2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Appears in 6415 patents — a generic fragment claimed broadly, so it's down-weighted as IP noise. Top by claim status then date:
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2376077-B1 | COMPOSITION AND METHOD FOR TREATMENT OF DIABETES | BIOKIER INC (US) | 2017-03-15 | — | — | EP | claimed |
| EP-1227813-B1 | REVERSE-TURN MIMETICS AS alpha 4ß INTEGRIN INHIBITORS | MYRIAD GENETICS INC (US) | 2007-08-22 | — | — | EP | claimed |
| US-12042505-B2 | Compositions and methods for treating dry eye | Genetic Disease Investigators, LLC (US) | 2024-07-23 | — | — | US | disclosed |
| US-20240239785-A1 | SUBSTITUTED 2-(2,6-DIOXOPIPERIDIN-3-YL)-5-(1-PIPERIDIN-4-YL)ISOINDOLINE-1,3-DIONE DERIVATIVES AND USES THEREOF | DANA-FARBER CANCER INSTITUTE, INC. | 2024-07-18 | — | — | US | disclosed |
| US-20240238271-A1 | PHARMACEUTICAL COMPOSITION FOR ENHANCING CELL KILLING, AND USE THEREOF | SHANGHAI JUNCELL THERAPEUTICS CO., LTD. (CN) | 2024-07-18 | — | — | US | disclosed |
| EP-4397376-A2 | COMBINATION COMPRISING AN MEK INHIBITOR AND A B-RAF INHIBITOR | Novartis AG (CH) | 2024-07-10 | — | — | EP | disclosed |
| US-20240217927-A1 | Methods of Making Deuterium-Enriched N-Acetylcysteine Amide (D-NACA) and (2R,2R)-3,3-Disulfanediyl BIS(2-Acetamidopropanamide) (DINACA) and Using D-NACA and DINACA to Treat Diseases Involving Oxidative Stress | NACUITY PHARMACEUTICALS, INC. | 2024-07-04 | — | — | US | disclosed |
| WO-2024145422-A1 | SYNTHESIS OF 2-PHENYL-2-AMINO-CYCLOHEXAN-1-ONE DERIVATIVES | GILGAMESH PHARMACEUTICALS, INC. (US) | 2024-07-04 | — | — | WO | disclosed |
| EP-4392025-A1 | ANTI-FUNGALS COMPOUNDS TARGETING THE SYNTHESIS OF FUNGAL SPHINGOLIPIDS | The Research Foundation for The State University of New York (US) | 2024-07-03 | — | — | EP | disclosed |
| US-12023332-B2 | Compositions and methods for activating signaling through the CB1 cannabinoid receptor for treating and preventing diseases and disorders characterized by abnormal cellular accumulation of sphingolipids such as sphingomyelin | WYLDER NATION FOUNDATION (US) | 2024-07-02 | — | — | US | disclosed |
| CN-118267479-A | Combination therapy using chemokine receptor 2 (CCR 2) antagonists and PD-1/PD-L1 inhibitors | 凯莫森特里克斯股份有限公司 | 2024-07-02 | — | — | CN | disclosed |
| EP-0533240-A2 | Substituted amine derivatives of piperazinylcamphorsulfonyl oxytocin antagonists | MERCK & CO. INC. (US) | 1993-03-24 | — | — | EP | disclosed |
| EP-0533242-A2 | Substituted derivatives of piperazinylcamphorsulfonyl oxytocin antagonists | MERCK & CO. INC. (US) | 1993-03-24 | — | — | EP | disclosed |
| EP-0532097-A1 | Piperazinyl(sulfon)amide derivatives of camphor as oxytocin antagonists | MERCK & CO. INC. (US) | 1993-03-17 | — | — | EP | disclosed |
| EP-0528586-A1 | Inhibiting osteoclast-mediated bone resorption using aminoalkyl-substituted phenyl derivatives | MERCK & CO. INC. (US) | 1993-02-24 | — | — | EP | disclosed |
| US-5137904-A | Useful in the treatment of atherosclerosis and thrombosis | G. D. SEARLE & CO. (US) | 1992-08-11 | — | — | US | disclosed |
| EP-0486280-A2 | Piperidinylcamphorsulfonyl oxytocin antagonists | MERCK & CO. INC. (US) | 1992-05-20 | — | — | EP | disclosed |
| EP-0478363-A2 | Novel sulfonamide fibrinogen receptor antagonists | MERCK & CO. INC. (US) | 1992-04-01 | — | — | EP | disclosed |
| EP-0478328-A1 | Novel fibrinogen receptor antagonists | MERCK & CO. INC. (US) | 1992-04-01 | — | — | EP | disclosed |
| EP-0434094-A1 | Methods of using 2-isopropyl-2-phenylaminovaleronitriles immunosuppresants and vasodilators | G.D. Searle & Co. (US) | 1991-06-26 | — | — | EP | disclosed |